These data agree with our studies using murine cells and demonstrate that IL-36α is capable of inducing a pro-inflammatory gut homing phenotype in human CD4+ T cells increasing the rationale for targeting IL-36 in the clinic to inhibit T cell mediated inflammation in IBD. This evidence concerns the gene IL36A and inflammatory bowel disease.